Study in Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA) Patients to Evaluate Work Productivity Before and After the Start of Adalimumab Therapy in Daily Practice in Belgium (SPACTIVE)

AbbVie

Status: Completed

Conditions: Psoriatic Arthritis; Ankylosing Spondylitis

Study type: Observational

Funder types: Industry

Identifiers

NCT01845818

P13-990

Details and patient eligibility

About

This observational study will document to what extent in daily clinical practice the work productivity is affected before and after the start of adalimumab treatment.

Changes in the employment status and work productivity of participants with AS and PsA before and after the start of adalimumab will be noted. The relationship between employment status, work productivity, disease activity and clinical evaluations will be evaluated. Since AS and PsA might be diseases with a strong impact on the daily life of the participant, an evaluation will be performed to the effect of the disease on quality of life and work productivity.

Enrollment: 183 patients

Sex: All

Ages: 18 to 50 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient >= 18 years and <= 50 years
• Patient diagnosed with AS or PsA
• Patient to be initiated on adalimumab (according to the Marketing Authorization and Belgian reimbursement criteria)
• Patient willing to sign informed consent

Exclusion criteria

• Any contraindication for adalimumab as specified in the corresponding Summary of Product Characteristics (SmPC)
• Patient previously treated with biologics
• Patient participating in other AbbVie-sponsored trials

Trial design

183 participants in 1 patient group

Ankylosing Spondylitis and Psoriatic Arthritis

Description:

Participants with AS and PsA and in whom adalimumab treatment is initiated. All medication will be prescribed in the usual manner in accordance with the terms of the marketing authorization and in line with the Belgian reimbursement criteria.